NY-WHITE-OPS
23.12.2020 17:08:14 CET | Business Wire | Press release
White Ops (“White Ops” or the “Company”), a global leader in protecting enterprises and internet platforms from digital fraud and abuse, today announced its acquisition by Goldman Sachs Merchant Banking Division, in partnership with ClearSky Security and NightDragon (together, the “Sponsors”). The Sponsors are acquiring the business from previous investors Paladin Capital Group, Grotech Ventures, and other shareholders, and the acquisition follows Goldman Sachs’ and ClearSky’s initial investment in the Company earlier this year . The acquisition has formally closed and terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201223005385/en/
The acquisition will support White Ops in its next phase of growth and further accelerate its expansion into new markets. The Company's core focus is to protect enterprises from sophisticated bot attacks and fraud across the domains of cybersecurity, digital advertising, and marketing, serving some of the largest enterprises and internet platforms. This year, as more companies moved to digital, White Ops was called upon on behalf of its customers to verify the humanity of more than 10 trillion interactions per week and growing, providing an incredibly broad and deep platform to stop nefarious activity across the internet. The company grew the number of customers it serves by 40% and employees of the company grew by 25% to 170.
“Goldman Sachs, ClearSky, and NightDragon are ideal partners to support the next phase of the Company’s evolution and growth across multiple markets, use cases and geographies,” said Tamer Hassan, CEO and co-founder of White Ops. “Their continued support of our mission to disrupt the economics of cybercrime, global network of relationships, and market expertise provides a very strong foundation to execute on our vision to enable collective protection for the internet.”
“We have been very pleased with the Company’s performance since our initial investment and we’re delighted to build on our current partnership, especially as White Ops continues to benefit from consumers’ shift to digital and clients increasingly require protection,” said Anthony Arnold, Managing Director at Goldman Sachs. “We look forward to supporting management in their next phase of growth.”
“White Ops’ highly differentiated technology platform and scaled signal collection footprint helps its clients protect against a wide range of sophisticated fraud types,” said Matthew Popper, Managing Director at Goldman Sachs. “We look forward to working with management and our partners at ClearSky and NightDragon to accelerate the Company’s expansion into new markets.”
"As fraud and abuse become increasingly prevalent across the digital ecosystem, enterprises and internet platforms require sophisticated threat protection now more than ever. White Ops has proven that it can stop fraud and abuse at tremendous scale," said Jay Leek, Managing Partner of ClearSky. "We have spent a lot of time with their leadership team over the past year and have been impressed with the strength and quality of their platform. We look forward to partnering to continue to build on the Company’s leadership position in the industry."
"Through our experience in engaging with hundreds of enterprises and their cybersecurity teams, we know that automated attacks on applications creating fraud and abuse is a critical point of risk to every security and marketing team," said Dave DeWalt, Founder and Managing Director at NightDragon. "We look forward to partnering with the team at White Ops to help clients across a range of industries."
In addition to representatives from Goldman Sachs, Jay Leek will join the Board of Directors representing ClearSky and Dave DeWalt will join the Board of Directors representing NightDragon and serve as Vice Chairman of the Company.
Morgan Stanley & Co. LLC acted as financial advisor to White Ops. Legal counsel was provided to White Ops by Cooley LLP.
The Sponsors were advised by Momentum Cyber. Legal counsel was provided to the Sponsors by Sullivan & Cromwell LLP and Wilson Sonsini Goodrich & Rosati.
Bad actors with millions of sophisticated bots at their disposal cause fraud at the rate of tens of billions of dollars a year against companies across the globe. These sophisticated bots live on consumer and enterprise devices, sharing browsing history and habits with real humans, which makes them especially difficult to detect. White Ops’ multilayered detection methodology, advanced algorithms, Satori Threat Intelligence and Research Team , and massive scale can detect and prevent these automated attacks at every level of sophistication, protecting customers’ sensitive data, reputation, compliance, bottom line and customer experience as they grow their digital business. These capabilities enabled White Ops to play a leading role in taking down 3ve , one of the largest fraud botnets to date, through collective protection and bringing together the largest private sector collaboration in history, including the FBI, Google, Facebook and many others in the industry. White Ops also recently uncovered ICEBUCKET , the largest and widest Connected TV (CTV) related fraud operation. In addition, White Ops recently announced availability of its products in the AWS Cloud Marketplace and the Snowflake Data Marketplace to provide customers even more ways to access the Company’s platform.
White Ops’ Fraud Mitigation Platform solves top cybersecurity pain points through its product offerings:
- Application Integrity - Protects sites and applications from digital fraud and abuse including account takeover attacks, new account fraud, fraudulent transactions and sensitive content scraping, preventing costly fraud losses while preserving user privacy and frictionless digital experiences.
- Marketing Integrity - Protects digital marketing investments from fraud and abuse including paid media, lead generation, and retargeting, preventing fraudulent traffic from entering marketing platforms to ensure efficiency and boost ROI.
- Advertising Integrity - Protects digital media and advertising from fraud and abuse within desktop, mobile, and CTV environments for trusted inventory and human-only impressions for more effective advertising.
To learn more about White Ops’ perspective on how this investment further advances their mission, read this blog post from CEO and co-founder Tamer Hassan: https://www.whiteops.com/blog/our-next-chapter
About White Ops
White Ops is a cybersecurity company that collectively protects global enterprises and internet platforms from digital fraud and abuse. We verify the humanity of more than 10 trillion interactions per week protecting our customers sensitive data, reputation, compliance, bottom line and customer experience as they grow their digital business. To learn more visit www.whiteops.com
About Goldman Sachs Merchant Banking Division
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. Goldman Sachs Merchant Banking Division (MBD) is the primary center for the firm’s long-term principal investing activity. MBD is one of the leading private capital investors in the world with investments across private equity, infrastructure, private debt, growth equity and real estate.
About ClearSky
ClearSky is a venture capital/growth equity firm that has been operating since 2012 with offices across the United States. ClearSky invests in companies that offer transformative security solutions with a specific focus on cybersecurity, critical infrastructure security, privacy, data governance and compliance. The firm’s world-class dedicated security team has a proven track record with over 60 years of security investing and practitioner experience. ClearSky also has a highly distinguished advisory board consisting of diverse business leaders and a Fortune 500 CISO Board of Advisors that is unmatched in the industry. For more information, visit http://clear-sky.com/
About NightDragon
NightDragon is an investment firm focused on investing in growth and late-stage companies within the cybersecurity industry. Its flexible model allows it to lead or co-invest alongside leading venture capital and private equity firms in the pursuit of driving growth and increasing shareholder value. NightDragon is unique in providing deep operational expertise in cybersecurity gained by its founders Dave DeWalt and Ken Gonzalez from years serving as senior executives leading technology companies such as Documentum, EMC, Siebel Systems (Oracle), McAfee, Mandiant, Avast, and FireEye. For more information, visit www.NightDragon.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005385/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
